Further, VISPO treated groups showed a significant decrease in the antiapoptotic protein Bcl-2, but increased expression of proapoptotic Bax as compared to BPH group (p < 0.01) (Fig. 7). The gene discussed is BCL2; the disease is benign prostatic hyperplasia.